Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock

Annals of Pharmacotherapy

Volumn 39, Issue 3, 2005, Pages 538-542

  Gerónimo Pardo, Manuel ^a   Cuartero Del Pozo, Ana B ^a   Jiménez Vizuete, José M ^a   Cortiñas Sáez, Manuel ^a   Peyró García, Ramón ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Calcium channel blockers; Captopril; Clarithromycin; Doxazosin; Erythromycin; Nifedipine; Vasodilatory shock

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLARITHROMYCIN; CYTOCHROME P450 3A4; DOXAZOSIN; NIFEDIPINE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; HEART BLOCK; HUMAN; HYPERTENSION; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SHOCK; VASCULAR RESISTANCE; VASODILATATION;

AGED; ANTI-BACTERIAL AGENTS; ANTIHYPERTENSIVE AGENTS; CLARITHROMYCIN; DRUG SYNERGISM; HEART BLOCK; HUMANS; HYPERTENSION; MALE; NIFEDIPINE; SHOCK;

EID: 13944250925     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E432     Document Type: Article

References (17)

1. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-95.
2. Iverson RL. Septic shock: a clinical perspective. Crit Care Clin 1988;4: 215-28.
3. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117-23.
4. Lip GYH, Ferner RE. Poisoning with anti-hypertensive drugs: calcium antagonists. J Hum Hypertens 1995;9:155-61.
5. Tsuruta S, Nakamura K, Arimori K, Nakano M. Effects of erythromycin, clarithromycin and rokitamycin on nifedipine metabolism in rats. Biol Pharm Bull 1997;4:411-6.
6. Liedholm H, Nordin G. Erythromycin-felodipine interaction. DICP 1991;25:1007-8.
7. Kaeser YA, Brunner F, Drewe J, Haefeli WE. Severe hypotension and bradycardia associated with verapamil and clarithromycin. Am J Health Syst Pharm 1998;55:2417-8.
8. Goldschmidt N, Azaz-Livshits T, Gotsman I, Nir-Paz R, Ben-Yehuda A, Muszkat M. Compound cardiac toxicity of oral erythromycin and verapamil. Ann Pharmacother 2001;35:1396-9. DOI 10.1345/aph.10396
9. Pearigen PD, Benowitz NL. Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine. Drug Saf 1991;6:408-30.
10. Donnelly R, Elliott HL, Meredith PA. Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists. Clin Pharmacokinet 1994;26:472-85.
11. Weisgerber K, Link A, Hammer B, Böhm M. [Vasopressin analogue injection as ultimate measure for counteracting severe catecholamine-refractory poisoning by several vasodilators taken with suicidal intent] German. Dtsch Med Wochenschr 2003;128:2189-92.
12. Ramoska EA, Spiller HA, Winter M, Borys D. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med 1993;22:196-200.
13. Kuvin JT. Electrocardiographic changes of hyperkalemia. N Engl J Med 1998;338:662.
14. Tiberti G, Bana G, Bossi M. Complete atrioventricular block with unwidened QRS complex during hyperkalemia. Pacing Clin Electrophysiol 1998;21:1480-2.
15. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists. An update. Clin Pharmacokinet 1992;22:416-33.
16. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995;21:612-20.
17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.